Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE):a double-blind, placebo-controlled, randomised, phase 3 study

Mannstadt, Michael, Clarke, Bart L, Vokes, Tamara, Brandi, Maria Luisa, Ranganath, Lakshminarayan, Fraser, William D, Lakatos, Peter, Bajnok, Laszlo, Garceau, Roger, Mosekilde, Leif, Lagast, Hjalmar, Shoback, Dolores and Bilezikian, John P (2013) Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE):a double-blind, placebo-controlled, randomised, phase 3 study. The Lancet Diabetes & Endocrinology, 1 (4). pp. 275-283. ISSN 2213-8587

Full text not available from this repository. (Request a copy)

Abstract

Hypoparathyroidism results in impaired mineral homoeostasis, including hypocalcaemia and hyperphosphataemia. Treatment with high-dose oral calcium and active vitamin D does not provide adequate or consistent control of biochemical indices and can lead to serious long-term complications. We aimed to test the efficacy, safety, and tolerability of once-daily recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) in adults with hypoparathyroidism.

Item Type:	Article
Additional Information:	Copyright © 2013 Elsevier Ltd. All rights reserved.
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User:	Pure Connector
Date Deposited:	07 Jul 2014 13:10
Last Modified:	19 Oct 2023 01:17
URI:	https://ueaeprints.uea.ac.uk/id/eprint/48849
DOI:	10.1016/S2213-8587(13)70106-2

Actions (login required)

View Item